ALEXANDRIA, Va., Dec. 2 -- United States Patent no. 12,485,188, issued on Dec. 2, was assigned to Skyline Therapeutics Ltd. (Cayman Islands, Great Britain).
"Recombinant adeno-associated virus with modified AAV capsid polypeptides" was invented by Yanqun Shu (Shanghai), Jinzhao Hou (Shanghai), Heping Li (Shanghai), Qiongqiong Ren (Shanghai), Lumei Xiao (Shanghai), Bing Wu (Shanghai) and Peilu Li (Shanghai).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a modified adeno-associated virus (AAV) capsid polypeptide and a novel recombinant adeno-associated virus (rAAV) comprising the modified AAV capsid polypeptide for delivering the gene product for the therapy. The present inventi...